{"id":"NCT01349465","sponsor":"Janssen R&D Ireland","briefTitle":"3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection","officialTitle":"A Prospective 3-Year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study With a TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07-04","primaryCompletion":"2016-01-05","completion":"2016-01-05","firstPosted":"2011-05-06","resultsPosted":"2017-02-16","lastUpdate":"2017-04-10"},"enrollment":249,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"No treatment","otherNames":[]}],"arms":[{"label":"Group 1: TMC 435 - Patients With SVR at LPVPS","type":"OTHER"},{"label":"Group 2: TMC 435 - Patients With No SVR at LPVPS","type":"OTHER"}],"summary":"The purpose of this study is to investigate durability of SVR in chronic HCV patients who achieved SVR in the previous study with TMC435-containing regimen and time for resistance associated mutations to return to baseline in chronic HCV patients who did not achieve SVR in the previous study with TMC435-containing regimen.","primaryOutcome":{"measure":"Percentage of Participants Maintaining SVR at the Last Available Visit","timeFrame":"Last Available Visit (Month 36 for subjects completing the study)","effectByArm":[{"arm":"SVR at Last Post-Therapy Follow-up Visit of Previous Study","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":48,"countries":["United States","Belgium","Canada","France","Germany","Poland","Russia"]},"refs":{"pmids":["29378602"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":200},"commonTop":["Bile duct stone","Cholecystitis chronic","Iron deficiency anaemia","Alpha 1 foetoprotein increased","Dysarthria"]}}